All In Biotech

Drug Trial Radar · NCT06519981

Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-9231 in Healthy Caucasian Participants

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Aug 21, 2024

Primary completion

Sep 29, 2024

Study completion Nov 27, 2024

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, randomized, double-blind, placebo-controlled study. The objective of this study is to evaluate the safety, tolerability, and PK profile of HRS-9231 injection following a single dose in healthy Caucasian participants.

Conditions

  • MRI

Interventions

  • HRS-9231or matching placeboDrug

    HRS-9231 injection or matching placebo will be administered through IV injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Day 8
  2. Vital signsTime frame: Day 8
  3. Physical examinationTime frame: Day 8
  4. LaboratoryTime frame: Day 8
  5. ECGTime frame: Day 8
  6. Injection site reactionTime frame: Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical research

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.